IL10 and COVID-19: In our recent research, we have demonstrated that exogenous delivery of IL-10 to whole-blood cells downregulates SARS-CoV-2 induced exacerbated inflammatory response, by reducing several pro-inflammatory mediators correlated with COVID-19 severity and by decreasing frequency and activation of IFN-γ producing CD4, CD8 T cells and NK cells (45).